國立虎尾科技大學 |

Asthma = targeted biological therapies /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Asthma/ by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli.
其他題名:	targeted biological therapies /
作者:	Pelaia, Girolamo.
其他作者:	Vatrella, Alessandro.
出版者:	Cham :Springer International Publishing : : 2017.,
面頁冊數:	vi, 99 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Asthma - Treatment. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-46007-9
ISBN:	9783319460079

Asthma = targeted biological therapies /
Pelaia, Girolamo.

Asthmatargeted biological therapies /[electronic resource] :by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli. - Cham :Springer International Publishing :2017. - vi, 99 p. :ill., digital ;24 cm.

Introduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.

This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.

ISBN: 9783319460079

Standard No.: 10.1007/978-3-319-46007-9doiSubjects--Topical Terms:

790117
Asthma
--Treatment.

LC Class. No.: RC591

Dewey Class. No.: 616.23806

Asthma = targeted biological therapies /
LDR:02538nam a2200313 a 4500 001 957424
003 DE-He213
005 20161112033317.0
006 m d
007 cr nn 008maaau
008 201118s2017 gw s 0 eng d
020 $a 9783319460079 $q (electronic bk.)
020 $a 9783319460055 $q (paper)
024 7 $a 10.1007/978-3-319-46007-9 $2 doi
035 $a 978-3-319-46007-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC591
072 7 $a MJL $2 bicssc
072 7 $a MED079000 $2 bisacsh
082 0 4 $a 616.23806 $2 23
090 $a RC591 $b .P381 2017
100 1 $a Pelaia, Girolamo. $3 1249001
245 1 0 $a Asthma $h [electronic resource] : $b targeted biological therapies / $c by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli.
260 $a Cham : $c 2017. $b Springer International Publishing : $b Imprint: Springer,
300 $a vi, 99 p. : $b ill., digital ; $c 24 cm.
505 0 $a Introduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.
520 $a This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.
650 0 $a Asthma $x Treatment. $3 790117
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Pneumology/Respiratory System. $3 668561
650 2 4 $a Allergology. $3 673940
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a General Practice / Family Medicine. $3 593966
650 2 4 $a Pediatrics. $3 644839
700 1 $a Vatrella, Alessandro. $3 1249002
700 1 $a Maselli, Rosario. $3 1249003
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46007-9
950 $a Medicine (Springer-11650)